CHAIRMAN, CEO & PRESIDENT, ASHVATTHA THERAPEUTICS
Redwood City, California, United States
Dr. Cleland has 30 years of industry experience in research & development, including more than a decade at Genentech. His experience in startups includes major roles in obtaining more than $450 million in capital at stages from Series A through D & exit via IPO including over $300 million in capital raised as CEO. As the founding CEO of Versartis (VSAR), he led one of top biotech IPOs of all time. He held executive management positions at BaroFold, Novacea and Targesome, & has managed directly all aspects of pharmaceutical development & late-stage research. While at Genentech, Dr. Cleland served in product development & manufacturing roles. He held important leadership roles in the successful approval of two drugs, Herceptin® & Nutropin Depot®, as well as in early work on Lucentis®, Avastin®, & Omnitarg®. He holds a BS in Chemical Engineering from the UC Davis and a PhD in Chemical Engineering from MIT Dr. Cleland has authored more than 100 articles & 4 books, & holds issued patents.